Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography
暂无分享,去创建一个
E. Shpall | J. Roszik | J. Gelovani | L. Flores | A. Najjar | S. Olivares | Tiejuan Mi | H. Huls | Dean Anthony Lee | R. Champlin | M. Alauddin | B. Rabinovich | L. Cooper | Vincenzo Paolillo | P. Manuri | N. Turkman
[1] Harjeet Singh,et al. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical‐grade T cells to target CD19 , 2014, Immunological reviews.
[2] Crystal Mackall,et al. Simplified process for the production of anti-CD19-CAR-engineered T cells. , 2013, Cytotherapy.
[3] E. Shpall,et al. Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood , 2013, Journal of visualized experiments : JoVE.
[4] E. Shpall,et al. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. , 2012, Human gene therapy.
[5] C. Bollard,et al. Good T cells for bad B cells. , 2012, Blood.
[6] David L. Porter,et al. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.
[7] S. Olivares,et al. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. , 2011, Cancer research.
[8] G. Dotti,et al. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. , 2010, Blood.
[9] E. Guinan,et al. Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. , 2010, Cancer research.
[10] P. Rao,et al. piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. , 2010, Human gene therapy.
[11] O. Mawlawi,et al. Repetitive Noninvasive Monitoring of HSV1-tk-Expressing T Cells Intravenously Infused into Nonhuman Primates Using Positron Emission Tomography and Computed Tomography with 18F-FEAU , 2009, Molecular imaging.
[12] W. Bornmann,et al. Molecular–Genetic PET Imaging Using an HSV1-tk Mutant Reporter Gene with Enhanced Specificity to Acycloguanosine Nucleoside Analogs , 2009, Journal of Nuclear Medicine.
[13] E. Shpall,et al. PET imaging of T cells derived from umbilical cord blood , 2009, Leukemia.
[14] Michel Sadelain,et al. Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy , 2009, Journal of immunotherapy.
[15] D. Paik,et al. Noninvasive detection of therapeutic cytolytic T cells with 18F–FHBG PET in a patient with glioma , 2009, Nature Clinical Practice Oncology.
[16] E. Shpall,et al. System Sleeping Beauty the Redirecting Specificity of T-cell Populations for Cd19 Using Cited Articles Citing Articles E-mail Alerts Redirecting Specificity of T-cell Populations for Cd19 Using the Sleeping Beauty System , 2022 .
[17] C. Bordignon,et al. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. , 2007, Blood.
[18] S. Kornblau,et al. Control of graft-versus-host disease with maintenance of the graft-versus-leukemia effect in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes. , 2007, Experimental hematology.
[19] R. Tsien,et al. Construction and validation of improved triple fusion reporter gene vectors for molecular imaging of living subjects. , 2007, Cancer research.
[20] W. Arap,et al. Molecular PET imaging of HSV1-tk reporter gene expression using [18F]FEAU , 2007, Nature Protocols.
[21] David D. Smith,et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. , 2006, Cancer research.
[22] H. Heslop,et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). , 2006, Blood.
[23] David D. Smith,et al. Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy. , 2006, Blood.
[24] E. Warren,et al. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. , 2006, Blood.
[25] H. Heslop,et al. Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease , 2004, The Journal of experimental medicine.
[26] R. Blasberg,et al. Cytoplasmically retargeted HSV1-tk/GFP reporter gene mutants for optimization of noninvasive molecular-genetic imaging. , 2003, Neoplasia.
[27] Michel Sadelain,et al. Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes , 2003, Nature Biotechnology.
[28] Sanjiv S Gambhir,et al. Quantitative imaging of the T cell antitumor response by positron-emission tomography , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[29] J. Barrio,et al. Human pharmacokinetic and dosimetry studies of [(18)F]FHBG: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[30] Zhanjiang Liu,et al. Effects of Insert Size on Transposition Efficiency of the Sleeping Beauty Transposon in Mouse Cells , 2001, Marine Biotechnology.
[31] S. Kornblau,et al. Preemptive control of graft-versus-host disease in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes. , 2001, Cancer research.
[32] S. Kornblau,et al. Production and culture of HSVtk transduced suicidal lymphocytes induces variable changes in the lymphocyte subset composition , 1999, Bone Marrow Transplantation.